Recent advances in genetics have determined that a number of epilepsy syndromes that occur in the first year of life are associated with genetic etiologies. These syndromes range from benign familial epilepsy syndromes to early-onset epileptic encephalopathies that lead to poor prognoses and severe psychomotor retardation. An early genetic diagnosis can save time and overall cost by reducing the amount of time and resources expended to reach a diagnosis. Furthermore, a genetic diagnosis can provide accurate prognostic information and, in certain cases, enable targeted therapy. Here, several early infantile epilepsy syndromes with strong genetic associations are briefly reviewed, and their genotype-phenotype correlations are summarized. Because the clinical presentations of these disorders frequently overlap and have heterogeneous genetic causes, next-generation sequencing (NGS)-based gene panel testing represents a more powerful diagnostic tool than single gene testing. As genetic information accumulates, genetic testing will likely play an increasingly important role in diagnosing pediatric epilepsy. However, the efforts of clinicians to classify phenotypes in nondiagnosed patients and improve their ability to interpret genetic variants remain important in the NGS era.

Key words: Infant, Epilepsy, Genetics

Introduction

Recent developments in molecular genetics have resulted in tremendous advances in the medical field. The increased understanding of genetics and the advancement of molecular technology have led to the identification of previously unknown causes of diseases, thereby facilitating the development of novel therapies. During the last decade, great progress has also been made in understanding the genetics underlying epilepsy. Among these factors, epilepsy syndromes that occur during the first year of life are interesting from a genetic standpoint. The incidence of epilepsy is high during the first year and then declines throughout childhood. Several symptomatic causes, including metabolic disorders and structural brain lesions, are the major causes of epilepsy during this period. However, seizures may occur in neonates and infants with normal neurologic or metabolic statuses and family histories of early-onset seizures. In addition, certain patients experience intractable seizures accompanied by psychomotor retardation. Genetic testing may be helpful in these cases. An accurate early genetic diagnosis is crucial not only for avoiding unnecessary investigation but also for enabling better treatment strategies in certain cases. A genetic diagnosis can also provide useful information regarding the natural history and prognosis of the disorder and much more accurate information regarding other at-risk family members than broad empirical risk assessments.

In this review, epilepsy syndromes with various prognoses beginning during the first year of life and appropriate genetic tests, particularly the epilepsy gene panel, are discussed.
Benign familial epilepsy syndromes in infancy

Three benign epilepsy syndromes with autosomal dominant inheritance patterns are recognized in infancy. These conditions are primarily differentiated by the age of onset with certain overlapping periods. The age of onset typically occurs before the fifth day of life in benign familial neonatal epilepsy (BFNE), between 2 days and 7 months of age in benign familial neonatal-infantile epilepsy (BFNIE), and between 3 and 8 months of age in benign familial infantile epilepsy (BFIE). The incidence of BFNE is estimated to be 14.4 per 1,000 live births\(^3\); the incidences of BFNIE and BFIE are unknown. These syndromes typically occur in previously normal neonates and infants. Afebrile focal and prominent motor seizures that are secondarily generalized predominate, and occasionally are associated with apnea, cyanosis, and staring. Interictal electroencephalograms (EEGs) are normal, and patients respond well to antiepileptic drugs. Developmental and intellectual outcomes are typically normal. A genetic diagnosis is crucial because these three conditions have significant clinical overlap.

1. Benign familial neonatal epilepsy

BFNE occurs at a mean age of approximately 3 days and remits at a mean age of 3 months. Up to 11% of affected patients suffer from subsequent seizures.\(^3\) This disorder was originally described in an Austrian family by Rett and Teubel.\(^4\) Subsequently, numerous BFNE families have been described, including many families with

| Epilepsy syndrome | Inheritance | Locus | Gene | Gene product |
|-------------------|-------------|-------|------|--------------|
| BFNE              | AD          | 20q13.33 | KCNQ2 | Subunit of voltage-gated K+ channel |
|                   |             | 8q24.22 | KCNQ3 | Subunit of voltage-gated Na+ channel |
| BFNIE             | AD          | 2q24   | SCN2A | - |
| BFIE              | AD          | 19q    |          | Protein-rich transmembrane protein 2 |
|                   |             | 16p11.2 | PRR2  | Subunit of voltage-gated Na+ channel |
|                   |             | 2q24.3 | SCN2A | - |
|                   |             | 1p36.12-p35.1 |          | Subunit of voltage-gated Na+ channel |
|                   |             | 12q13  | SCN8A | Aristaless-related homeobox |
| Ohtahara          | XR          | Xp21  | ARX   | Solute carrier family 25, member 25 |
|                   | AR          | 11p15.5 | SLC25A22 | Syntaxin binding protein 1 |
|                   | AD          | 9q34.11 | STXB1 | Subunit of voltage-gated K+ channel |
|                   | AD          | 20q13.33 | KCNQ2 | Aristaless-related homeobox |
| Infantile spasms  | XR          | Xp21  | ARX   | Cyclin-dependent kinase-like 5 |
|                   | XD          | Xp22.13 | CDKL5 | Subunit of UDP-N-acetylgalactosaminyltransferase |
|                   | XD          | Xq23   | ALG13 | Syntaxin binding protein 1 |
|                   | AD          | 9q34.11 | STXB1 | α subunit of voltage-gated N channel |
|                   | AD          | 2p24.3 | SCN1A | α subunit of voltage-gated N channel |
|                   | AD          | 2q24.3 | SCN2A | Subunit of GABAa receptor |
|                   | AD          | 15q12  | GABRB3 | Dynamin subfamily of GTP-binding protein |
|                   | AD          | 9q34.11 | DNM1  | α subunit of voltage-gated N channel |
|                   | AD          | 2p24.3 | SCN1A | γ subunit of GABAa receptor |
|                   | AD          | 5q34   | GABRG2 | α subunit of GABAa receptor |
|                   | AD          | 5q34   | GABRA1 | δ protocadherin subclass of the cadherin superfamily |
|                   | XL          | Xq22.1 | PCD1H9 | α subunit of voltage-gated N channel |
| Dravet            | AD          | 2q24.3 | SCN2A | α subunit of voltage-gated N channel |
|                   | AD          | 12q13.13 | SCN8A | Glucose transporter protein type 1 |
| Glucose1 transporter deficiency syndrome | AR, AD | 1p34.2 | SLC2A1 | α-aminoadipic semialdehyde dehydrogenase |
| Pyridoxine-dependent seizures | AR | 5q23.2 | ALDH7A1 | Pyridoxal 5′-phosphate oxidase |
| Pyridoxal-phosphate-responsive seizures | AR | 17q21.32 | PNPO | Folate receptor α |
| Folate deficiency  | AR          | 11q13.4 | FOLR  | |

BFNE, benign familial neonatal epilepsy; BFNIE, benign familial neonatal-infantile epilepsy; BFIE, benign familial infantile epilepsy; AD, autosomal dominant; AR, autosomal recessive; XR, X-linked recessive; XD, X-linked dominant; XL, X-linked; GABA, γ-aminobutyric acid. Adapted from the Online Mendelian Inheritance in Man database (https://www.ncbi.nlm.nih.gov/omim/).
potassium channel subunit mutations, particularly in KCNQ2 and KCNQ3 (Table 1).

An analysis of a cohort of unrelated BNFE patients yielded mutation frequencies of 56% for KCNQ2 and 6.6% for KCNQ3. A recent study involving 33 families with BFNE reported 27 families with a KCNQ2 mutation and one family with a KCNQ3 mutation, demonstrating that the KCNQ2 mutation is the most common mutation in BFNE. KCNQ2 and KCNQ3 encode voltage-gated potassium channel subunits Kv7.2 and Kv7.3. Kv7.2 and Kv7.3 form the heteromeric channel responsible for the M-current, which stabilizes the resting membrane potential and is therefore important for regulating neuronal excitability.

Interestingly, KCNQ2 mutations may present with a distinct phenotype characterized by neonatal seizures that evolve to drug-resistant epileptic encephalopathy and mental retardation (Table 2). In these patients, the age of seizure onset and seizure type is similar to that of BFNE, but the seizures are resistant to therapy, and the seizure frequency gradually decreases over the first 5 years of life. EEGs show a burst-suppression pattern during the first few days of life, followed by multifocal epileptiform activities. During childhood, most patients suffer from profound intellectual disabilities and neurological abnormalities, such as hypotonia or spastic quadriplegia.

2. Benign familial neonatal-infantile epilepsy

BFNIE occurs between 2 days and 7 months of age and tends to remit by 1 year of age. This condition exhibits autosomal dominant inheritance and is often caused by a missense mutation in SCN2A, which encodes the α2 subunit of the voltage-gated sodium channel. This mutation increases the sodium current, leading to increased neuronal excitability. BFNIE was first described as an intermediate phenotype between BFNE and BFIE. BFNIE is similar to BFNE, but the average age of onset differs; thus, these disorders cannot be consistently distinguished based on the age of onset. BFNIE is particularly difficult to diagnose in small families with limited clinical information, highlighting that genetic testing is the best and only method to distinguish BFNE from BFNIE.

Similar to the KCNQ2 mutation, the SCN2A mutation has a large range of phenotypes, including BFNIE and a variety of epilepsy syndromes, such as genetic epilepsy with febrile seizure plus (GEFS+), Dravet syndrome, and certain intractable childhood epilepsies. The mutations identified in intractable epilepsies alter the channel properties of NaV1.2 more than BFNIE mutations do, suggesting the mechanism of more severe epileptic phenotypes.

3. Benign familial infantile epilepsy

BFIE occurs between 3 and 8 months of age, and the seizures spontaneously remit before the age of 3 years. Seizures are typically not observed later in life; however, certain cases develop paroxysmal dyskinesia or paroxysmal kinesigenic choreoathetosis during adolescence. Interestingly, this gene mutation was first identified as causing paroxysmal kinesigenic dyskinesia, and mutations in the same gene were subsequently reported in families with BFIE or ICCA. PRRT2, which is located at chromosomal region 16p11.2, encodes a proline-rich transmembrane protein that is mainly expressed in the brain, i.e., the cerebral cortex and basal ganglia. The function of PRRT2 is currently unknown, but this gene may interact with synaptoosomal-associated protein 25 kDa, which is involved in releasing neurotransmitters from synaptic vesicles. Currently, PRRT2 is among the main causes of BFIE and accounts for up to 70% of BFIE families.

Table 2. Genotype-phenotype relationship of primary genes associated with benign familial epilepsies during infancy and early-onset epileptic encephalopathies

| Gene  | Epilepsy syndromes                                      |
|-------|---------------------------------------------------------|
| KCNQ2 | Benign familial neonatal epilepsy                       |
|       | Ohtahara syndrome or EIEE7                              |
| KCNQ3 | Benign familial neonatal epilepsy                       |
| SCN2A | Benign familial neonatal infantile epilepsy            |
|       | Genetic epilepsy with febrile seizures plus             |
| PRRT2 | Benign familial infantile epilepsy                      |
|       | Infantile convulsion and choreoathetosis syndrome       |
| STXB1 | Ohtahara syndrome or EIEE4                              |
|       | West syndrome                                           |
| ARX   | Nonsyndromic intellectual disability with or without epilepsy |
| SLC25A22 | Ohtahara syndrome or EIEE3                          |
|       | Early myoclonic epilepsy                                |
| CDKL5 | West syndrome or EIEE2                                  |
| SCN1A | Dravet syndrome or EIEE6                                 |
| SCN8A | Genetic epilepsy with febrile seizure plus              |
|       | EIEE13                                                  |
Epileptic encephalopathies

Certain children with seizures beginning during the first year of life have serious outcomes, including refractory epilepsy and psychomotor retardation. Epileptic encephalopathies are characterized by recurrent seizures and prominent interictal epileptiform discharges during the early infantile period.20 The numerous etiologies of epileptic encephalopathies are primarily associated with structural brain defects and inherited metabolic disorders. However, many pathogenic gene mutations could be involved in the development of epileptic encephalopathies. To date, more than 100 genes including STXB1, ARX, SLC25A22, KCNQ2, CDKL5, SCN1A, SCN1A, POLG, SC2A1, and PCDH19 have been defined to be associated with early-onset epileptic encephalopathies.12,20,30 These genes are classified as early infantile epileptic encephalopathy (EIEE) types and have been reported up to EIEE58 (https://www.ncbi.nlm.nih.gov/omim/).

1. Ohtahara syndrome

Ohtahara syndrome is characterized by intractable seizures during the first few weeks to months of the neonatal period, suppression–burst patterns on interictal EEGs, and poor developmental outcomes.31 The prognosis is typically grave, including severe psychomotor retardation and high mortality, particularly during the early stages of the disorder. Structural brain anomalies, inborn errors of metabolism, genetic abnormalities, and unknown factors are involved in the pathogenesis of Ohtahara syndrome. To date, various genes that play essential roles in the neuronal and interneuronal functions of the brain have been associated with Ohtahara syndrome. Syntaxin-binding protein 1 (STXBPI), which regulates the release of synaptic vesicles and the secretion of neurotransmitters, is the most important cause of Ohtahara syndrome.23,31 Other genes include aristaless-related homeobox (ARX), which acts as a regulator of the proliferation and differentiation of neuronal progenitors31; solute carrier family 25 member 22 (SLC25A22), which encodes a mitochondrial glutamate transporter32; and potassium voltage-gated channel (KCNQ2), which plays a key role in the generation and transmission of electrical signals.33

2. Infantile spasms (West syndrome)

The main characteristics of infantile spasms include developmental regression and a characteristic hypsarrhythmia on interictal EEGs.34 The spasms typically start between 4 and 6 months of age with clustering and are typically observed as an infant awakes from or falls to sleep. The hypsarrhythmic EEG pattern consists of random, high voltage, nonsynchronous spikes and slow waves of variable duration and topography.34 A fraction of the symptomatic causes of infantile spasms, including chromosomal abnormalities, hypoxic ischemic encephalopathy, and intracranial infection, has been steadily increasing due to improved diagnostic techniques.35 The developmental outcome of infants with infantile spasms is poor. Mental retardation is recorded in approximately 70% to 80% of cryptogenic infantile spasm cases and 85% to 90% of symptomatic infantile spasm cases.36 Although infants with cryptogenic infantile spasms have better prognoses than infants with symptomatic infantile spasms, the outcome of infants with cryptogenic infantile spasms remains poor.37 ARX and CDKL5 are among the genes most frequently associated with infantile spasms. The other reported mutations are summarized in Table 1.

3. Dravet syndrome

Dravet syndrome or severe myoclonic epilepsy of infancy is a rare epileptic encephalopathy. This disease is characterized by generalized febrile or hemiconvulsive seizures starting during the first year of life, followed by multiple types of intractable afebrile seizures and psychomotor retardation.38 At its presentation, interictal EEGs and brain imaging are normal, which often delays diagnosis. The seizures are refractory to antiepileptic drug therapy, and the affected patients have a high mortality rate due to the increased risk of status epilepticus and sudden unexpected death.39 Sodium channel blockers, such as lamotrigine and carbamazepine, should be avoided, while valproic acid, topiramate, clobazam, and stiripentol may be beneficial.39 SCN1A has been implicated in the phenotype of 70%–80% of patients with Dravet syndrome.39 This gene encodes a voltage-gated sodium channel and is mainly associated with neuronal excitability. SCN1A has also been associated with generalized epilepsy with febrile seizure plus (GEFS+).40 The identification of a mutation in SCN1A is important for the early diagnosis and appropriate treatment of Dravet syndrome. However, not all patients exhibit SCN1A mutations. Various genes, including GABR2, SCN2A, and SCN8A, have also been reported to cause Dravet syndrome.41,42

Application of an epilepsy gene panel in patients with epilepsy syndromes during the first year of life: benefits and limitations

Many studies have attempted to elucidate the genetics of epilepsy over the past 2 decades. Many advances have been made, such as the complexities of phenotype-genotype relationships and the discovery of numerous genes associated with epilepsy.44 Several genetic testing methods are currently available (Table 3). Sanger sequencing is preferentially indicated in patients with well-defined phenotypes associated with a single gene mutation and is the gold standard for detecting small sequence variations. To increase the diagnostic yield of this test, clinical expertise leading to the suspicion of a causative gene is required. Sanger sequencing enables the screening of only one gene at a time and is often expensive and time consuming because several rounds of testing are needed. On the other hand, NGS is a high-throughput DNA sequencing technology
that can analyze thousands of genes in a single reaction.\textsuperscript{45,46} Using NGS, a targeted gene panel including only phenotypically relevant genes has become available. Currently, several commercial epilepsy gene panels, each containing 70–465 genes, are available.\textsuperscript{47} As research studies increase our current understanding, new genes will be added to the list.

Epilepsy gene panels are cost-effective time-saving methods of simultaneously examining multiple genes associated with a disease, particularly in various infantile epilepsy syndromes, with which multiple genes are associated.\textsuperscript{20,29} Epilepsy gene panels also simplify the decision-making process for the ordering physician. Several studies have demonstrated the diagnostic yield of gene panels. A German study reported that 16 of 33 patients (48\%) with epileptic disorders were successfully diagnosed using a targeted epilepsy gene panel of 265 genes.\textsuperscript{48} Ortega-Moreno et al.\textsuperscript{49} reported that in 17 of 87 patients (19.5\%), disease-causing variants were able to be identified via a gene panel with the highest yield in patients with early-onset epileptic encephalopathies. In a study of 400 patients with early-onset epilepsy and developmental delay tested with a gene panel, 30 of 77 (39\%) of those with seizure onset within the first 2 months had a causative mutation.\textsuperscript{49} Recently, Mercimek-Mahmutoglu et al.\textsuperscript{50} reported that targeted epilepsy gene panels have increased the diagnostic yield from <10\% to >25\% in patients with epileptic encephalopathy. These authors insisted that epilepsy gene panels are a cost-effective alternative to Sanger sequencing of individual genes for the genetic diagnosis of epilepsy. However, gene panel testing has several limitations. Because the gene panels include only genes that have been previously identified, a disease caused by a mutation of a previously unknown gene could be missed. Several researchers question the usefulness of gene panels in an era during which new genes are discovered daily at high rates.

Considering which genes to include in a panel applied in genetic testing is important. Genes that are strongly associated with a disorder should certainly be included to increase the diagnostic yield. However, if physicians include all genes that are remotely associated with a phenotype under the assumption that more is better, the gene of interest may ultimately be revealed to not be the cause of the phenotype. Therefore, close communication between clinicians and laboratory geneticists is essential for selecting the appropriate gene panel because the gene panel should be understood by the ordering physician from a clinical perspective.

Finally, targeted NGS is not technically an independent diagnostic test and requires confirmation using a second method. Complementary Sanger sequencing is often required due to the low coverage and no-coverage exons, and complementation using a single nucleotide polymorphism array is required to detect the copy-number variations in the targeted genes.

Whole exome sequencing (WES) enables the investigation of all exons in the genome and could be performed if a genetic disease without a specific available test is suspected or if the specific genetic tests are negative.\textsuperscript{51} This method can discover new genes if a number of patients with similar phenotypes carry similar variants.\textsuperscript{52} However, WES is expensive and time consuming, which combined with the complexity of interpreting WES data, prevents many physicians from ordering this analysis as a first-line test.

### Conclusions

In conclusion, benign familial neonatal/infantile epilepsies and epileptic encephalopathies have a wide variety of genetic etiologies, and new genetic causes are continually discovered. Epilepsy gene panel testing using NGS can be useful for patients with epilepsy syndromes during the first year of life because clinical diagnosis is difficult and multiple genes are implicated although there are several limitations. Its application is currently covered by the Korean National Health Insurance since 2017 in 17 institutions. The dramatically reduced cost of genetic testing and the accumulation of genetic information could enable genetic testing as a part of routine pediatric epilepsy diagnosis before long. The role of the clinician in selecting the best genetic testing method remains important, and the clinician plays a role in interpreting whether an identified genetic variant is causing a child’s phenotype.

| Method                  | Indications                                                                 | Advantages                                                                 | Disadvantages                                                                 |
|------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Single-gene test       | Distinct clinical findings clearly implicating a specific gene (e.g., achondroplasia and Dravet syndrome) | Identifies nearly all mutations at a specific locus, No incidental findings | Limitations in detecting trinucleotide repeat disorders and epigenetic abnormalities, May require complementary tests |
| Gene panel             | Disorders with overlapping phenotypes                                      | Rapid, Low cost                                                           | Only tests the genes on the panel, Fewer VURs than WES                        |
| Whole exome sequencing | Extreme heterogeneity with multiple nonspecific features                   | Covers entire human coding sequence, Discovery of de novo mutations        | Many VUR and incidental findings, Requires Sanger sequencing for confirmation |

VUR, variant of unknown significance; WES, whole exome sequencing.
**Conflicts of interest**

No potential conflict of interest relevant to this article was reported.

**Acknowledgments**

This study was supported by the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science, ICT and Future Planning (NRF-2017R1C1B5076772).

**References**

1. Deprez L, Jansen A, De Jonghe P. Genetics of epilepsy syndromes starting in the first year of life. Neurology 2009;72:273-81.
2. Ottman R, Hirose S, Jain S, Lerche H, Lopes-Cendes I, Noebels JL, et al. Genetic testing in the epilepsies—report of the ILAE Genetics Commission. Epilepsia 2010;51:655-70.
3. Plouin P, Anderson V. Benign familial and non-familial neonatal seizures. In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, editors. Epileptic syndromes in infancy, childhood and adolescence. 3rd ed. Montrouge: John Libbey, 2002:3-13.
4. Rett A, Teubel R. Neugeborenenkrampfe im Rahmen einer epileptisch belasteten Familie. Wien Klin Wochenschr 1964;76:609-13.
5. Singh NA, Westenskow P, Charlier C, Pappas C, Leslie J, Dillon J, et al. KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions: expansion of the functional and mutation spectrum. Brain 2003;126(Pt 12):2726-37.
6. Grinton BE, Heron SE, Pelekanos JT, Kivity S, Afawi Z, et al. Familial neonatal seizures in 36 families: Clinical and genetic features correlate with outcome. Epilepsia 2015;56:1071-80.
7. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, et al. A potassium channel mutation in neonatal human epilepsy. Science 1998;279:403-6.
8. Charlier C, Singh NA, Ryan SG, Lewis TB, Rees BE, Leach RJ, et al. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet 1998;18:53-5.
9. Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998;18:25-9.
10. Borgatti R, Zucca C, Cavallini A, Ferrario M, Panzeri C, Castaldo P, et al. A novel mutation in KCNQ2 associated with BFNC, drug resistant epilepsy, and mental retardation. Neurology 2004;63:609-13.
11. Dedek K, Fusco L, Teloy N, Steinlein OK. Neonatal convulsions and epileptic encephalopathy in an Italian family with a missense mutation in the fifth transmembrane region of KCNQ2. Epilepsy Res 2003; 54:21-7.
12. Steinlein OK, Conrad C, Weidner B. Benign familial neonatal convulsions: always benign? Epilepsy Res 2007;73:245-9.
13. Weckhuysen S, Mandelstam S, Suls A, Audenaert D, Deconinck T, Claes LR, et al. KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann Neurol 2012;71:15-25.
14. Dedek K, Kunath B, Kanamura C, Reuner U, Jentsch TJ, Steinlein OK. Myokymia and neonatal epilepsy caused by a mutation in the voltage sensor of the KCNQ2 K+ channel. Proc Natl Acad Sci U S A 2001;98:12272-7.
15. Wuttke TV, Jurkat-Rott K, Paulus W, Gamcarek M, Lehmann-Horn F, Lerche H. Peripheral nerve hyperexcitability due to dominant-negative KCNQ2 mutations. Neurology 2007;69:2045-53.
16. Zhou X, Ma A, Liu X, Huang C, Zhang Y, Shi R, et al. Infantile seizures and other epileptic phenotypes in a Chinese family with a missense mutation of KCNQ2. Eur J Paediatr 2006;165:691-5.
17. Berkovic SF, Heron SE, Giordano L, Martini C, Guerrini R, Kaplan RE, et al. Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy. Ann Neurol 2004;55:550-7.
18. Heron SE, Crossland KM, Andermann E, Phillips HA, Hall AJ, Bleasle A, et al. Sodium-channel defects in benign familial neonatal-infantile seizures. Lancet 2002;360:851-2.
19. Scalfani P, Rusconi R, Armatura E, Zara F, Avanzini G, Franceschetti S, et al. Effects in neocortical neurons of mutations of the Na(v)1.2 Na+ channel causing benign familial neonatal-infantile seizures. J Neurosci 2006;26:10100-9.
20. Xu R, Thomas EA, Jenkms M, Gazina EV, Chiu C, Heron SE, et al. A childhood epilepsy mutation reveals a role for developmentally regulated splicing of a sodium channel. Mol Cell Neurosci 2007;35:292-301.
21. Mulley JC, Heron SE, Dibbens LM. Proposed genetic classification of the "benign" familial neonatal and infantile epilepsies. Epilepsia 2011;52:649-50.
22. Shi X, Yasumoto S, Kurahashi H, Nakagawa E, Fukasawa T, Uchiya S, et al. Clinical spectrum of SCN2A mutations. Brain Dev 2012;34:541-5.
23. Vigevano F, Fusco L, Di Capua M, Ricci S, Sebastianelli R, Lucchinetti P. Benign infantile familial convulsions. Eur J Paediatr 1992;151:608-12.
24. Heron SE, Grinton BE, Kivity S, Afawi Z, Zuberi SM, Hughes JN, et al. PRRT2 mutations cause benign familial infantile epilepsy and infantile convulsions with choreothetosis syndrome. Am J Hum Genet 2012;90:152-60.
25. Schubert J, Paravidino R, Becker F, Berger A, Bebek N, Bianchi A, et al. PRRT2 mutations are the major cause of benign familial infantile seizures. Hum Mutat 2012;33:1439-43.
26. Ono S, Yoshirou K, Kinoshita A, Kikuchi T, Nakane Y, Kato N, et al. Mutations in PRRT2 responsible for paroxysmal kinesigenic dyskinesias also cause benign familial infantile convulsions. J Hum Genet 2012;57:338-41.
27. Wang JL, Cao L, Li XH, Hu ZM, Li JD, Zhang JG, et al. Identification of PRRT2 as the causative gene of paroxysmal kinesigenic dyskinesias. Brain 2011;134( Pt 12):3493-501.
28. Dulac O. Epileptic encephalopathy. Epilepsia 2001;42 Suppl 3:23-6.
29. Gürsoy S, Erçal D. Diagnostic approach to genetic causes of early-onset epileptic encephalopathy. J Child Neurol 2016;31:523-32.
30. Scheffer IE, Berkovic SF. The genetics of human epilepsy. Trends Pharmacol Sci 2003;24:428-33.
31. Ohtahara S, Yamatogi Y. Epileptic encephalopathies in early infancy with suppression-burst. J Clin Neurophysiol 2003;20:398-407.
32. Saitsu H, Kato M, Mizuguchi T, Hamada K, Osaka H, Tohyama J, et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat Genet 2008;40:782-8.
33. Kato M, Saitoh S, Kamei A, Shiraiishi H, Ueda Y, Akasaka M, et al. A longer polyalanine expansion mutation in the ARX gene causes early infantile epileptic encephalopathy with suppression-burst pattern (Ohtahara syndrome). Am J Hum Genet 2007;81:361-6.
34. Molinari F, Kaminska A, Fierrmonte G, Bodlaert N, Raas-Rothschild A, Plouin P, et al. Mutations in the mitochondrial glutamate carrier SLC25A22 in neonatal epileptic encephalopathy with suppression-bursts. Clin Genet 2009;76:188-94.
35. Pavone P, Striano P, Falsaperla R, Pavone L, Ruggieri M. Infantile spasms syndrome, West syndrome and related phenotypes: what we
36. Swaiman KF, Ashwal S, Ferriero DM. Pediatric neurology: principles & practice. 4th ed. St. Louis (MO): Elsevier Health Sciences, 2006.

37. Widjaja E, Go C, McCoy B, Sneed OC. Neurodevelopmental outcome of infantile spasms: A systematic review and meta-analysis. Epilepsy Res 2015;109:155-62.

38. Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy (Dravet syndrome). In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, editors. Epileptic syndromes in infancy, childhood and adolescence. 4th ed. Montrouge: John Libbey, 2005:89-113.

39. Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia 2011;52 Suppl 2:72-5.

40. Marini C, Scheffer IE, Nabbout R, Suls A, De Jonghe P, Zara F, et al. The genetics of Dravet syndrome. Epilepsia 2011;52 Suppl 2:24-9.

41. Escayg A, Goldin AL. Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia 2010;51:1650-8.

42. Larsen J, Carvill GL, Gardella E, Kluger G, Schmiedel G, Barisic N, et al. The phenotypic spectrum of SCN8A encephalopathy. Neurology 2015;84:480-9.

43. Nakamura K, Kato M, Osaka H, Yamashita S, Nakagawa E, Hagiwara K, et al. Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome. Neurology 2013;81:992-8.

44. Helbig I, Lowenstein DH. Genetics of the epilepsies: where are we and where are we going? Curr Opin Neurol 2013;26:179-85.

45. Lemke JR, Riesch E, Scheurenbrand T, Schubach M, Wilhelm C, Steiner I, et al. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. Epilepsia 2012;53:1387-98.

46. Xue Y, Ankala A, Wilcox WR, Hegde MR. Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing. Genet Med 2015;17:944-51.

47. Chambers C, Jansen LA, Dhamija R. Review of commercially available epilepsy genetic panels. J Genet Couns 2016;25:213-7.

48. Ortega-Moreno L, Giráldez BG, Soto-Insuga V, Losada-Del Pozo R, Rodrigo-Moreno M, Alarcón-Morcillo C, et al. Molecular diagnosis of patients with epilepsy and developmental delay using a customized panel of epilepsy genes. PLoS One 2017;12:e0188978.

49. Trump N, McTague A, Brittain H, Papandreou A, Meyer E, Ngoh A, et al. Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis. J Med Genet 2016;53:310-7.

50. Mercimek-Mahmutoglu S, Patel J, Cordeiro D, Hewson S, Callen D, Donner EJ, et al. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. Epilepsia 2015;56:707-16.

51. ACMG Board of Directors. Points to consider in the clinical application of genomic sequencing. Genet Med 2012;14:759-61.

52. Epi4K Consortium; Epilepsy Phenome/Genome Project, Allen AS, Berkovic SF, Cossette P, Delanty N, et al. De novo mutations in epileptic encephalopathies. Nature 2013;501:217-21.

https://doi.org/10.3345/kjp.2018.61.4.101